Karyopharm price target raised to $13 from $8 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Karyopharm (KPTI) to $13 from $8 and keeps a Buy rating on the shares. The firm sees a greater probability of approval for Xpovio in endometrial cancer. Exploratory subgroup analysis from the Phase 3 SIENDO trial showed that Xpovio maintenance therapy resulted in a 65% reduction in the risk of progression or death, the analyst tells investors in a research note.